Mycophenolate Mofetil for Ocular Inflammation

American Journal of Ophthalmology

Volumn 149, Issue 3, 2010, Pages

  Daniel, Ebenezer ^a   Thorne, Jennifer E ^b,c   Newcomb, Craig W ^a   Pujari, Siddharth S ^d   Kaçmaz, R Oktay ^d,k   Levy Clarke, Grace A ^e,f   Nussenblatt, Robert B ^f   Rosenbaum, James T ^g,h   Suhler, Eric B ^g,i   Foster, C Stephen ^d,j   Jabs, Douglas A ^a,k   Kempen, John H ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^e St Luke's Cataract and Laser Institute   (United States)

^f NATIONAL EYE INSTITUTE   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ PORTLAND VA MEDICAL CENTER   (United States)

^j HARVARD MEDICAL SCHOOL   (United States)

^k MOUNT SINAI SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CHILD; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EYE INFLAMMATION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTERMEDIATE UVEITIS; IRIDOCYCLITIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MUCOUS MEMBRANE PEMPHIGOID; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SCLERITIS; SIDE EFFECT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UVEITIS;

EID: 76749162797     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2009.09.026     Document Type: Article

References (27)

1. Nussenblatt R.B. The natural history of uveitis. Int Ophthalmol 14 (1990) 303-308
2. Jabs D.A., Rosenbaum J.T., Foster C.S., et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130 (2000) 492-513
3. Lau C.H., Comer M., and Lightman S. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Experiment Ophthalmol 31 (2005) 487-491
4. Doycheva D., Deuter C., Stuebiger N., Biester S., and Zierhut M. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol 91 (2007) 180-184
5. Siepmann K., Huber M., Stubiger N., et al. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis. A retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol 244 (2006) 788-794
6. Zierhut M., Stübiger N., Siepmann K., et al. MMF and eye disease. Lupus 14 Suppl 1 (2005) S50-S54
7. Allison A.C. Mechanisms of action of mycophenolate mofetil. Lupus 14 (2005) S2-S8
8. Carr S.F., Papp E., Wu J.C., and Natsumeda Y. Characterization of human type I and type II INP dehydrogenases. J Biol Chem 268 (1993) 27286-27290
9. Iaccarino L., Arienti S., Rampudda M., et al. Mycophenolate mofetil in lupus glomerulonephritis: effectiveness and tolerability. Ann N Y Acad Sci 1110 (2007) 516-524
10. Appel G.B., Radhakrishnan J., and Ginzler E.M. Use of mycophenolate mofetil in autoimmune and renal diseases. Transplantation 80 (2005) S265-S271
11. Galor A., Jabs D.A., Leder H.A., et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology 115 (2008) 1826-1832
12. Thorne J.E., Jabs D.A., Qazi F.A., et al. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 112 (2005) 1472-1477
13. Choudhary A., Harding S.P., Bucknall R.C., and Pearce I.A. Mycophenolate mofetil as an immunosuppressive agent in refractory inflammatory eye disease. J Ocul Pharmacol Ther 22 (2006) 168-175
14. Teoh S.C., Hogan A.C., Dick A.D., and Lee R.W. Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol 146 (2008) 752-760
15. Saw V.P., Dart J.K., Rauz S., et al. Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. Ophthalmology 115 (2008) 253-261
16. Nogueras F., Espinosa M.D., Mansilla A., Torres J.T., Cabrera M.A., and Martin-Vivaldi R. Mycophenolate mofetil-induced neutropenia in liver transplantation. Transplant Proc 37 (2005) 1509-1511
17. Kempen J.H., Daniel E., Gangaputra S., et al. Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol 15 (2008) 47-55
18. Gangaputra S., Newcomb C.W., Liesegang T.L., et al., Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Methotrexate for ocular inflammatory diseases. Ophthalmology 116 (2009) 2188-2198
19. Pasadhika S., Kempen J.H., Newcomb C., et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol 148 (2009) 500-509
20. Schimmer B.P., and Parker K.L. Adrenocorticotropic hormone; Adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Brunton L.L., and Parker K.L. (Eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics (2006), The McGraw-Hill Companies, New York 1587-1613
21. Thorne J.E., Woreta F.A., Jabs D.A., and Anhalt G.J. Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy. Ophthalmology 115 (2008) 2146-2152
22. Kempen J.H., Gangaputra S., Daniel E., et al. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol 146 (2008) 802-812
23. Kempen J.H., Daniel E., Dunn J.P., et al. Risk of overall and cancer mortality among patients with ocular inflammation treated with immunosuppressive therapy: retrospective cohort study. BMJ 339 (2009) b2480
24. Sobrin L., Christen W., and Foster C.S. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology 115 (2008) 1416-1421
25. Ostensen M., Lockshin M., Doria A., et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology 47 (2000) 28-31
26. Huang S.Y., Chueh H.Y., Shaw S.W., et al. Sonographic diagnosis of fetal malformations associated with mycophenolate mofetil exposure in utero. Am J Obstet Gynecol 199 (2008) 6-8
27. Jabs D.A., Nussenblatt R.B., and Rosenbaum J.T. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140 (2005) 509-516